


Viral Epidemiology Snapshot: September 15-21, 2024


Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV						
<u>Virus</u>	#Tested	#Positive	% Positive			
Flu A	386	2	0.5%			
Flu B	386	0	0.0%			
RSV	313	3	1.0%			
CoV-2	688	77	11.2%			

Bacterial Respiratory Infections (Molecular Tests)						
<u>Organism</u>	#Tested	#Positive	% Positive			
Bordetella parapertussis	301	0	0.0%			
Bordetella pertussis	301	6	2.0%			
Chlamydia pneumoniae	294	0	0.0%			
Mycoplasma pneumoniae	300	16	5.3%			

Other Respiratory Viruses						
<u>Virus</u>	#Tested	#Positive	% Positive			
Adenovirus	294	5	1.7%			
Coronavirus 229E	294	0	0.0%			
Coronavirus HKU1	294	0	0.0%			
Coronavirus NL63	294	0	0.0%			
Coronavirus OC43	294	0	0.0%			
Metapneumovirus	294	0	0.0%			
Rhinovirus/Enterovirus	294	151	51.4%			
Parainfluenza 1	294	10	3.4%			
Parainfluenza 2	294	0	0.0%			
Parainfluenza 3	294	1	0.3%			
Parainfluenza 4	294	1	0.3%			





Flu A Subtyping				
2009 H1N1	1			
Seasonal H1	0			
Seasonal H3	0			
No Subtype	1			
Pending subtype	0			

This report contains results for all tests ordered throughout the CHMCA network. As of 9/19/23, the data set includes all Point of Care Testing performed at ACHPs and Urgent Care Centers, as well as the central hospital laboratories.

As of 10/1/23, SARS-CoV-2 will be tracked in total, rather than in "Diagnostic" and "Screening" categories

The top chart displays the 8-week trend for total number of positive tests for Flu A, Flu B, RSV, and SARS-CoV-2.

The bottom chart displays the 8week trend for positivity rate (# positive/ total # tested) Flu A, Flu B, RSV, and SARS-CoV-2.

